CR10404A - Composicion farmaceutica de liberacion sostenida sobre la base de un sistema de liberacion que comprende un polimero acido-soluble y un polimero ph-dependiente - Google Patents

Composicion farmaceutica de liberacion sostenida sobre la base de un sistema de liberacion que comprende un polimero acido-soluble y un polimero ph-dependiente

Info

Publication number
CR10404A
CR10404A CR10404A CR10404A CR10404A CR 10404 A CR10404 A CR 10404A CR 10404 A CR10404 A CR 10404A CR 10404 A CR10404 A CR 10404A CR 10404 A CR10404 A CR 10404A
Authority
CR
Costa Rica
Prior art keywords
liberation
polymer
acid
basis
pharmaceutical composition
Prior art date
Application number
CR10404A
Other languages
English (en)
Inventor
Rajesh Jain
Kour Chand Jindal
Sampath Kumar Devarajan
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of CR10404A publication Critical patent/CR10404A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen composiciones farmaceuticas de liberacion sostenida que comprenden por lo menos un agente activo escasamente soluble, por lo menos un solubilizante, un sistema polimerico controlador de velocidad de liberacion que consiste en un polimero soluble en acido y un polimero dependiente del pH, y opcionalmente otros excipientes farmaceuticamente aceptables; la presente invencion tambien describe un procedimiento para preparar tales composiciones y metodos de uso de las mismas; las composiciones de liberacion sostenida son utiles para proveer concentraciones terapeuticamente efectivas de los agentes activos durante periodos prolongados.
CR10404A 2006-03-27 2008-10-27 Composicion farmaceutica de liberacion sostenida sobre la base de un sistema de liberacion que comprende un polimero acido-soluble y un polimero ph-dependiente CR10404A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN832DE2006 2006-03-27

Publications (1)

Publication Number Publication Date
CR10404A true CR10404A (es) 2008-12-08

Family

ID=38540835

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10404A CR10404A (es) 2006-03-27 2008-10-27 Composicion farmaceutica de liberacion sostenida sobre la base de un sistema de liberacion que comprende un polimero acido-soluble y un polimero ph-dependiente

Country Status (14)

Country Link
US (1) US20100234288A1 (es)
EP (1) EP2004150A1 (es)
JP (1) JP2009531420A (es)
CN (1) CN101410096A (es)
AU (1) AU2007230549A1 (es)
BR (1) BRPI0709222A2 (es)
CA (1) CA2647421A1 (es)
CR (1) CR10404A (es)
EA (1) EA200870379A1 (es)
MA (1) MA30359B1 (es)
MX (1) MX2008012486A (es)
RS (1) RS20080439A (es)
TN (1) TNSN08365A1 (es)
WO (1) WO2007110878A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
EP2268283A2 (en) * 2008-03-12 2011-01-05 Dexcel Ltd. Oral modified-release formulations containing thiazepines
EP2108365A1 (en) * 2008-04-09 2009-10-14 LEK Pharmaceuticals d.d. Single dosage pharmaceutical formulation comprising eprosartan mesylate
EP2317980A2 (en) * 2008-08-11 2011-05-11 Ratiopharm GmbH Pharmaceutical compositions of rivaroxaban with modified release properties
CN101361979B (zh) * 2008-09-19 2011-01-19 天津博科林药品包装技术有限公司 一种固体制剂薄膜包衣剂及其制备方法
WO2010082855A1 (en) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
CN102281881A (zh) * 2010-02-26 2011-12-14 上海沪美医药科技有限公司 一种含有喹硫平的控(缓)释制剂及其制备方法和用途
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
AU2011288256A1 (en) * 2010-08-10 2013-02-07 Lupin Limited Oral controlled release pharmaceutical compositions of Blonanserin
CN103379917B (zh) * 2010-11-01 2016-10-12 梅琳塔治疗公司 药物组合物
CN102058517A (zh) * 2010-12-31 2011-05-18 泰州万全医药科技有限公司 一种帕潘立酮缓释剂及其制备方法
EP2868319A4 (en) * 2012-06-29 2016-02-24 Maruishi Pharma ORAL PHARMACEUTICAL PREPARATION OF ARIPIPRAZOLE
TWI722988B (zh) * 2015-06-05 2021-04-01 瑩碩生技醫藥股份有限公司 緩釋性醫藥組合物及其製備方法
CN105199115B (zh) * 2015-10-27 2021-01-12 中国林业科学研究院林产化学工业研究所 一种多孔渗水的三维网状结构的可注射水凝胶的制备及其应用
WO2017218772A1 (en) * 2016-06-17 2017-12-21 The Procter & Gamble Company Delayed-release particles
CN108203508A (zh) * 2016-12-16 2018-06-26 中国石油化工股份有限公司 一种改性尼龙6材料及其制备方法
BR112019012573A2 (pt) 2016-12-20 2019-11-19 Lts Lohmann Therapie Systeme Ag sistema terapêutico transdérmico que contém asenapina e polissiloxano ou poli-isobutileno
WO2018115001A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
KR101813835B1 (ko) * 2017-02-17 2017-12-29 이충근 피이지 프리 가용화제 및 이의 제조방법
CN107028903B (zh) * 2017-05-03 2020-03-10 深圳万和制药有限公司 布南色林片剂药物组合物及其制备方法
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
JP2021505595A (ja) 2017-12-05 2021-02-18 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 結晶形およびその製造方法
MX2020005518A (es) 2017-12-05 2020-11-06 Sunovion Pharmaceuticals Inc Mezclas no racemicas y usos de las mismas.
US11672781B2 (en) 2018-05-07 2023-06-13 Prana Biosciences Inc Metaxalone formulations
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CN109984999B (zh) * 2019-04-28 2021-12-24 重庆仁泽医药科技有限公司 一种药物组合物及其制备方法和用途
JP2022535893A (ja) 2019-06-04 2022-08-10 サノビオン ファーマシューティカルズ インク 放出調節製剤およびその使用
CN111568856B (zh) * 2020-06-24 2021-07-06 珠海舒桐医疗科技有限公司 一种阴道凝胶制剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
KR100694667B1 (ko) * 1999-12-08 2007-03-14 동아제약주식회사 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제
DE60233874D1 (de) * 2001-06-22 2009-11-12 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release

Also Published As

Publication number Publication date
CA2647421A1 (en) 2007-10-04
TNSN08365A1 (en) 2009-12-29
MX2008012486A (es) 2008-10-10
MA30359B1 (fr) 2009-04-01
WO2007110878A1 (en) 2007-10-04
BRPI0709222A2 (pt) 2011-07-12
RS20080439A (en) 2009-05-06
CN101410096A (zh) 2009-04-15
JP2009531420A (ja) 2009-09-03
US20100234288A1 (en) 2010-09-16
AU2007230549A1 (en) 2007-10-04
EP2004150A1 (en) 2008-12-24
EA200870379A1 (ru) 2009-04-28

Similar Documents

Publication Publication Date Title
CR10404A (es) Composicion farmaceutica de liberacion sostenida sobre la base de un sistema de liberacion que comprende un polimero acido-soluble y un polimero ph-dependiente
CY1109117T1 (el) Διαμορφωσεις enaιωphmatoς, οι οποιες περιλαμβανουν δραστικον συστατικο, επιφανειακως δρωσαν ουσια poloxamer ή meroxapol και γλυκολη, χρησις του δια την βιομηχανικην παρασκευην φαρμακου προς νοσηλειαν οφθαλμικων διαταραχων
AR065039A1 (es) Una composicion farmaceutica de liberacion modificada, un proceso para su preparacion, un metodo para su utilizacion y su uso
NZ746271A (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
AR058620A1 (es) Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo
ECSP088560A (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
ATE391708T1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
AR045068A1 (es) Formulacion de liberacion inmediata de composiciones farmaceuticas
DK2029121T3 (da) Transdermalt terapeutisk system indeholdende partikler af virksom bestanddel og med forøget strøm af virksom bestanddel
AR057319A1 (es) Composicion para la administracion topica y metodo para evitar o tratar infeccion o infestacion endoparasitica y ectoparasitica en un animal de sangre caliente
CO2019004190A2 (es) Formulaciones liposomales para uso en el tratamiento del cáncer
GT200500349A (es) Formulaciones de benzoxazoles substituidos
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
AR066372A1 (es) Formulaciones de aminoacidos n-halogenados con compuestos antiinflamatorios
PE20050439A1 (es) Forma de dosificacion farmaceutica de liberacion prolongada
CR9567A (es) Formulacion de liberacion prolongada de principios activos que presentan una solubilidad dependiente del ph
AR074689A1 (es) Formulaciones farmaceuticas de desintegracion rapida pre-compactadas de compuestos con baja biodisponibilidad oral. proceso de preparacion
PA8546201A1 (es) Agentes antibacterianos
AR050149A1 (es) Sistema de administracion de principio activo formado por un parche, que contiene principio activo, y al menos un agente regulador de la administracion de principio activo.
PE20071274A1 (es) Agente desfoliante a base de tidiazuron y benzofuranos
AR087155A1 (es) Formulacion granulada de azaperona de rapida disolucion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)